SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter
2019 financial results and provide a corporate update on
Thursday, November 7, 2019, after the
close of the U.S. financial markets. The Company will host a
conference call and live webcast to discuss the results with the
investment community the same day at 4:30 PM
EST.
Conference Call & Webcast Information
When:
Thursday, November 7, 2019, at
4:30 PM EST
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 2598434
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website. A replay of the conference
call will be archived under the investor relations section of
Arena's website for 30 days after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune-mediated inflammatory diseases,
is being evaluated in later-stage clinical programs in inflammatory
bowel disease (IBD), a Phase 2 program in atopic
dermatitis (AD), as well as progressing programs for other
potential indications. Arena is also evaluating olorinab (APD371)
in a Phase 2 program for gastrointestinal pain. Arena continues to
assess other earlier research and development stage drug
candidates, including APD418 for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – Phase 1), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's upcoming conference call and live webcast
with the investment community, Arena's drive, and the potential of
Arena's assets, programs, licenses, and partnerships. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-third-quarter-2019-financial-results-and-provide-corporate-update-on-november-7-300948776.html
SOURCE Arena Pharmaceuticals, Inc.